Payment overview · 2025
General Payments
$1,692.04
88 reported records · 18 companies
Healthcare provider profile · identity verified
Daniel A Herring, DO
Allopathic & Osteopathic Physicians|Family Medicine · CLYDE, OH · NPI 1528028990
Verified facts
What the public records show
CMS Open Payments records show Daniel A Herring, DO received $1,692.04 in general payments during 2025 across 88 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fanapt, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $411.05 | 24.3% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $218.42 | 12.9% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $211.88 | 12.5% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.70 | 8.9% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $133.44 | 7.9% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.06 | 4.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $67.05 | 4.0% | 4 | 2025 |
| Solta Medical, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $65.45 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.21 | 3.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.67 | 2.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.69 | 2.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.58 | 2.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.14 | 2.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $37.80 | 2.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.18 | 2.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.22 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.01 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.49 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,692.04 | 88 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $280.98 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $274.41 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $135.76 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $133.44 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $122.44 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $105.93 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.93 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.41 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.66 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $79.06 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $67.05 | 4 | 2025 |
Source payment records
|
|||||
| CLEAR+BRILLIANT Normalized: clear brilliant |
Not specified | Solta Medical, a division of Bausch Health US, LLC | $65.45 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.46 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.21 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.29 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.67 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FANAPT fanapt |
2025 | Fanapt | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
134 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 715 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 410 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 69 |
| Montelukast Sodium | Montelukast Sodium | 344 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 342 | 53 |
| Furosemide | Furosemide | 326 | 54 |
| Sertraline Hcl | Sertraline Hcl | 323 | 34 |
| Buspirone Hcl | Buspirone Hcl | 321 | 28 |
| Omeprazole | Omeprazole | 315 | 47 |
| Trazodone Hcl | Trazodone Hcl | 281 | 31 |
| Gabapentin | Gabapentin | 256 | 35 |
| Losartan Potassium | Losartan Potassium | 251 | 58 |
| Guanfacine Hcl | Guanfacine Hcl | 250 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 233 | 14 |
| Lamotrigine | Lamotrigine | 230 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 228 | 13 |
| Lisinopril | Lisinopril | 213 | 49 |
| Meloxicam | Meloxicam | 202 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 28 |
| Eliquis | Apixaban | 185 | 25 |
| Potassium Chloride | Potassium Chloride | 185 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 176 | 17 |
| Famotidine | Famotidine | 154 | 18 |
| Olanzapine | Olanzapine | 150 | suppressed |
| Simvastatin | Simvastatin | 150 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 36 |
| Metformin Hcl | Metformin Hcl | 141 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 23 |
| Linzess | Linaclotide | 134 | 13 |
| Levetiracetam | Levetiracetam | 130 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 129 | suppressed |
| Carvedilol | Carvedilol | 128 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 22 |
| Mirtazapine | Mirtazapine | 113 | 14 |
| Allopurinol | Allopurinol | 111 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 13 |
| Lithium Carbonate | Lithium Carbonate | 104 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 104 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 15 |
| Alprazolam | Alprazolam | 99 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 14 |
| Alendronate Sodium | Alendronate Sodium | 86 | 13 |
| Prednisone | Prednisone | 85 | 55 |
| Lorazepam | Lorazepam | 84 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 81 | 14 |
| Carbamazepine | Carbamazepine | 80 | suppressed |
| Cephalexin | Cephalexin | 79 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 22 |
| Spironolactone | Spironolactone | 79 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 72 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 72 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 15 |
| Azithromycin | Azithromycin | 68 | 52 |
| Ezetimibe | Ezetimibe | 68 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 65 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 65 | 11 |
| Xarelto | Rivaroxaban | 64 | suppressed |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Pregabalin | Pregabalin | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 12 |
| Baclofen | Baclofen | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Risperidone | Risperidone | 56 | suppressed |
| Atenolol | Atenolol | 55 | 11 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Fanapt | Iloperidone | 52 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 52 | suppressed |
| Lactulose | Lactulose | 52 | suppressed |
| Paliperidone Er | Paliperidone | 52 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 51 | suppressed |
| Latanoprost | Latanoprost | 50 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 28 |
| Haloperidol | Haloperidol | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 11 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 30 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Cefdinir | Cefdinir | 42 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 31 |
| Primidone | Primidone | 36 | suppressed |
| Carbamazepine Er | Carbamazepine | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Topiramate | Topiramate | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 22 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Zonisamide | Zonisamide | 30 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 29 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Felbamate | Felbamate | 26 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 20 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 20 | 20 |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Loperamide | Loperamide Hcl | 18 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Aviane | Levonorgestrel/Ethin.Estradiol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,692.04 · 88 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, Briviact, CLEAR+BRILLIANT, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LYBALVI, MOUNJARO, Nayzilam, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fanapt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error